At a glance
ClinicalIndex Comparison Record- ✓Lung cancer or lung metastases with lung, endobronchial, pleural, or mediastinal tumors progressing on systemic therapy or intolerant to systemic therapy
- ✓Tumors not amenable to resection, thermal ablation, or ablative radiation therapy
- ✓Lung-dominant disease with majority of active tumor volume in the chest
- ✓Age ≥18 years
- ✕ECOG performance status >2
- ✕Oxygen saturation <92% on room air
- ✕FEV1 <60%
- ✕No measurable treatable disease per RECIST v1.1; lung nodules all <1 cm or unable to measure on CT
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Lung Chemoemobolization
In Brief
A Phase 2 clinical trial evaluating Computed Tomography, Ethiodized Oil, and 3 other interventions for Lung Non-Small Cell Carcinoma and 6 related conditions. Currently recruiting, targeting 30 participants across 2 sites.
Detailed Summary
This phase II trial evaluates how well transarterial chemoembolization (TACE) works for treating patients with non-small cell lung cancer or lung metastases. TACE is a minimally invasive procedure that involves injecting chemotherapy directly into an artery that supplies blood to tumors, and then blocking off the blood supply to the tumors. Mitomycin (chemotherapy), Lipiodol (drug carrier), and Embospheres (small plastic beads that block off the artery) are injected into the tumor-feeding artery. This traps the chemotherapy inside the tumor and also cuts off the tumor\'s blood supply. As a result, the tumor is exposed to a high dose of chemotherapy, and is also deprived of nutrients and oxygen. TACE can be effective at controlling or stopping the growth of lung tumors.
Study Details
Timeline
Interventions
Undergo CT
Given IA
Given IA
Undergo TACE
Given IA